Sintilimab: A Promising Anti-Tumor PD-1 Antibody, PMID: 33324564
Sintilimab: First Global Approval, PMID: 30742278
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC, PMID: 32036071
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11), PMID: 32781263
Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit, PMID: 31402780
Recent updates on Sintilimab in solid tumor immunotherapy, PMID: 33292551
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial, PMID: 30612710
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients, PMID: 33241036
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial, PMID: 32795349
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11), PMID: 33246599
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study, PMID: 33070260
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer, PMID: 32981596
Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression, PMID: 32973816
Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab, PMID: 32304999
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma, PMID: 30612711
Antibodies to watch in 2019, PMID: 30516432
Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin: a case report, PMID: 32692239
Sintilimab, a PD-1 Inhibitor, Completely Reversed Rarely Refractory Hypofibrinogenemia in a Gastric Cancer Patient: A Case Report and Review of the Literature, PMID: 33194584
Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review, PMID: 33363038
Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report, PMID: 32656988
Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab, PMID: 32662522
Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer: A case report and literature review, PMID: 34106616
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12), PMID: 34048947
Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis, PMID: 32386943
Withdrawn: Effectiveness and safety of toripalimab, camrelizumab and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients, PMID: 32627214
Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report, PMID: 32481252
Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy, PMID: 32109851
Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature, PMID: 33545801
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies, PMID: 31362369
The binding epitope of sintilimab on PD-1 revealed by AbMap, PMID: 33637989
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study, PMID: 34143971
Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report, PMID: 32233637
Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma, PMID: 32309397
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients, PMID: 32643323
Sintilimab in Treating Advanced Lung Squamous Cell Carcinoma After Fourth-Line Treatment of Anlotinib Resistance, PMID: 34145167
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428], PMID: 33736838
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC, PMID: 33524601
Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma, PMID: 34364744
Complete pathological response with diabetic ketoacidosis to the combination of sintilimab and anlotinib in an unresectable hepatocellular carcinoma patient: a case report, PMID: 34338239
The approval of sintilimab for classical Hodgkin's lymphoma: views and perspectives of anti-PD-1/PD-L1 antibodies in China, PMID: 33928222
Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer, PMID: 34290784
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC), PMID: 33517977
Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation, PMID: 34109111
Discovery of New Immune Checkpoints: Family Grows Up, PMID: 32185707
A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient: A case report, PMID: 34397833
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study, PMID: 34358724
Sustained remission of multi-line relapsed extranodal NK/T-cell lymphoma, nasal type, following sintilimab and chidamide: A case report, PMID: 33725836
Severe immune-related hyperthermia followed by immune-related pneumonitis with PD-1 inhibitor (sintilimab) in small cell lung cancer: A case report, PMID: 33949137
Pazopanib together with 6-8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma, PMID: 34159088
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report, PMID: 33907417
For research use only. Not for human or drug use.
